- Home
- CRDF vs EMIS Comparison
CRDF vs EMIS Comparison
Compare CRDF & EMIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.16
N/A
Current Price
$9.97
Company Overview
Basic Information| Metric | CRDF | EMIS |
|---|---|---|
| Founded | 1999 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1M | 157.1M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRDF | EMIS |
|---|---|---|
| Price | $2.16 | $9.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.63 | N/A |
| AVG Volume (30 Days) | ★ 730.8K | 137.4K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $501,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.90 | $9.90 |
| 52 Week High | $5.64 | $11.11 |
Technical Indicators
Market Signals| Indicator | CRDF | EMIS |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | N/A |
| Support Level | $2.03 | N/A |
| Resistance Level | $2.37 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 55.32 | 0.00 |
Price Performance
Historical Comparison CRDF
EMIS
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About EMIS Emmis Acquisition Corp. Class A Ordinary Shares
Emmis Acquisition Corp is a blank check company.